Fig. 3: Persistence or acquisition of novel defined premalignant CHIP like mutations vs CHOP like mutations are prognostic in AML with mutated NPM1.
From: Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
A, B Survival analysis of patients with NPM1mut AML stratified by clonal evolution patterns of novel defined CHIP-like mutations vs oncogenic mutations. Based on the clonal evolution analysis on diagnosis, remission and relapse samples we redefined CHIP-like mutations (DNMT3A, TET2, SRSF2, IDH2, and IDH1) versus all other mutations (CHOP-like). A Kaplan–Meier plots depicting event-free survival (EFS, left panel and OS, right panel) of NPM1mut AML patients based on the persistency/acquisition of CHIP vs CHOP like mutations at CMR. P values were calculated with the log-rank test and p values for pairwise comparisons are given. B Cox proportional hazards multivariate model incorporating clonal evolution patterns by the presence/absence of CHOP-like mutations at CMR, clinical/molecular risk factors and allogeneic hematopoietic stem-cell transplantation. Overall survival (OS) hazard ratio (HR) at 95% confidence interval and p values for each variable are given.
